Mary Anne Trabaud
Overview
Explore the profile of Mary Anne Trabaud including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
118
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Amstutz A, Speich B, Mentre F, Rueegg C, Belhadi D, Assoumou L, et al.
Lancet Respir Med
. 2023 Feb;
11(5):453-464.
PMID: 36828006
Background: Interpretation of the evidence from randomised controlled trials (RCTs) of remdesivir in patients treated in hospital for COVID-19 is conflicting. We aimed to assess the benefits and harms of...
2.
Saker K, Pozzetto B, Bal A, Valette M, Fassier J, Saade C, et al.
Clin Chem
. 2022 May;
68(7):984-986.
PMID: 35639802
No abstract available.
3.
Trouillet-Assant S, Albert Vega C, Bal A, Nazare J, Fascia P, Paul A, et al.
BMJ Open
. 2020 Nov;
10(11):e041268.
PMID: 33234651
Introduction: The COVID-19 pandemic caused by SARS-CoV-2 threatens global public health, and there is an urgent public health need to assess acquired immunity to SARS-CoV-2. Serological tests might provide results...
4.
Raymond S, Nicot F, Pallier C, Bellecave P, Maillard A, Trabaud M, et al.
Clin Infect Dis
. 2017 Dec;
66(10):1588-1594.
PMID: 29244143
Background: Minority resistant variants of human immunodeficiency virus type 1 (HIV-1) could influence the virological response to treatment based on nonnucleoside reverse transcriptase inhibitors (NNRTIs). Data on minority rilpivirine-resistant variants...
5.
Saison J, Boulch D, Chidiac C, Demaret J, Malcus C, Cotte L, et al.
Open Forum Infect Dis
. 2015 Jun;
2(2):ofv063.
PMID: 26110165
Background. The primary aim of this study was to determine the impact of regulatory T cells (Tregs) percentage on immune recovery in human immunodeficiency virus (HIV)-infected patients after antiretroviral therapy...
6.
Raymond S, Maillard A, Amiel C, Peytavin G, Trabaud M, Desbois D, et al.
J Antimicrob Chemother
. 2015 Feb;
70(6):1858-64.
PMID: 25700719
Objectives: Virological failure (VF) in patients on maraviroc-based treatment has been associated with altered HIV tropism and resistance to maraviroc. This multicentre study aimed to characterize VF in patients treated...
7.
van Deursen P, Oosterlaken T, Andre P, Verhoeven A, Bertens L, Trabaud M, et al.
J Clin Virol
. 2009 Dec;
47(2):120-5.
PMID: 20018560
Background: HIV-1 RNA plasma level is a key parameter for anti-viral treatment monitoring in HIV-1 infected individuals. Plasma stability and accurate measurement of clinical state is at risk when transporting...
8.
Diaz O, Cubero M, Trabaud M, Quer J, Icard V, Esteban J, et al.
J Med Virol
. 2007 Dec;
80(2):242-6.
PMID: 18098146
Hepatitis C viruses in the blood of chronically infected patients are heterogeneous in density with the presence of lipoprotein associated viral particles of lower density than conventional virions. If low-density...
9.
Trabaud M, Cotte L, Labernardiere J, Lebel-Binay S, Icard V, Tardy J, et al.
J Acquir Immune Defic Syndr
. 2007 Jul;
46(2):134-44.
PMID: 17621239
Background: Genotypic and phenotypic resistance in 11 HIV-1-infected patients receiving enfuvirtide (ENF), as part of a salvage regimen, has been evaluated. Methods: Resistance mutations were detected by sequencing the gp41...